Management of Uncontrolled Diabetes with Microalbuminuria

Immediate Glycemic Management

The American Diabetes Association recommends aggressive insulin titration as the first priority for patients with an A1C of 10.3% 1, 2.
Timely dose titration is critical and should not be delayed, with both basal and prandial insulin doses adjusted based on self-monitoring blood glucose levels 2, 3, 4.
The basal insulin should be titrated to achieve appropriate fasting blood glucose levels first, and if fasting glucose is controlled but A1C remains elevated, the prandial insulin doses need intensification 2, 3, 4.

The presence of microalbuminuria mandates addition of an SGLT2 inhibitor or GLP-1 receptor agonist with demonstrated cardiovascular and renal benefit, independent of the A1C level 1.
SGLT2 inhibitors can be continued with insulin therapy to improve glucose control, reduce total daily insulin dose, and provide renal protection 4, 5.
GLP-1 receptor agonists are generally preferred to insulin intensification when possible, but in this case with A1C 10.3%, they should be added to—not substituted for—the existing insulin regimen 1.

If the patient is not already on metformin and has no contraindications, it should be added immediately 1.
Metformin can be safely continued with complex insulin regimens, and is effective, safe, inexpensive, and may reduce risk of cardiovascular events and death 1, 2, 3, 4, 6.

The high microalbumin ratio indicates diabetic kidney disease requiring specific intervention beyond glycemic control alone 1.
SGLT2 inhibitors with demonstrated renal benefit should be strongly prioritized 1.

Increase Lantus dose to achieve fasting glucose 80-130 mg/dL, and adjust Humalog doses based on pre-meal and 2-hour post-meal glucose readings 2, 3, 4.
Initiate SGLT2 inhibitor for renal protection with microalbuminuria 1, 5.
Add metformin if not contraindicated and not already prescribed, and continue metformin with insulin therapy 1, 2, 3, 4, 6.

Do not continue with inadequate insulin doses hoping for spontaneous improvement, as this represents severe hyperglycemia requiring immediate action 1, 2, 3.
Do not fail to address the microalbuminuria with appropriate cardio-renal protective medications, as the presence of kidney disease changes the treatment paradigm and mandates specific agent selection 1.
Counsel patients on SGLT2 inhibitor ketoacidosis risk, particularly the need to stop the medication during acute illness 5.
Avoid therapeutic inertia, as the combination of severe hyperglycemia and evidence of microvascular complications demands aggressive, multi-pronged intervention now 1, 7, 8.